Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-18 (canceled).

19. (previously presented) A unit dosage composition for administration to a human patient, comprising a liquid suspension of cellular material including from about 10,000 to 10,000,000 apoptotic cells and/or apoptotic bodies per kilogram of patient body weight, wherein said apoptotic bodies and/or apoptotic cells exhibit at least two characteristics comprising DNA fragmentation, surface exposure of phosphatidylserine, or altered mitochondrial membrane permeability.

Claims 20-46 (canceled).

47. (previously presented) The unit dosage composition of Claim 19, wherein the dosage contains from about 500,000 to about 5,000,000 apoptotic bodies and/or apoptotic cells per kilogram of body weight of said patent.

48. (previously presented) The unit dosage composition of Claim 47, wherein the dosage contains from about 1,500,000 to about 4,000,000 apoptotic bodies and/or apoptotic cells per kilogram of body weight of said patent.

Claims 49-53 (canceled).

54. (previously presented) A unit dosage composition for administration to a human patient, comprising a liquid suspension of cellular material including from about 10,000 to 10,000,000 apoptotic cells and/or apoptotic bodies per kilogram of patient body weight, wherein said

apoptotic cells and/or apoptotic bodies exhibit at least two characteristics comprising the binding of Fas ligands to Fas receptors, caspase activation, DNA fragmentation, surface exposure of phosphatidylserine, altered mitochondrial membrane permeability, or release of mitochondrial cytochrome-c.

Claim 55 (canceled).